CJC-1295 without DAC (Mod GRF 1-29) sourced from verified Chinese manufacturer. HPLC-verified, purity tested per batch. Research use only.
CJC-1295 Without DAC is a research compound available through our china peptide catalog as a finished, lyophilized vial from an established Chinese manufacturer. It belongs to the GHRH Analogue (Growth Hormone Releasing Hormone) Also Known As Modified GRF (1-29), Mod GRF 1-29, Sermorelin analogue
Available Variants
| Name | Strength | Pack Size | Purity | Availability |
|---|---|---|---|---|
| CJC-1295 Without DAC | 2 mg | 10 vials | ≥98% | In Stock |
| CJC-1295 Without DAC | 5 mg | 10 vials | ≥98% | In Stock |
| CJC-1295 Without DAC | 10 mg | 10 vials | — | In Stock |
| CJC-1295 Without DAC | 10 mg | 10 vials | ≥98% | In Stock |
Specification Highlights
Quality & Testing
Testing method: HPLC / LC-MS . Products are supplied against the specification shown on the applicable product page. The standard catalog purity specification is ≥98% unless otherwise stated. Product-specific specifications and quality-control information may vary by compound and batch. Available documentation: .
**Where provided, these documents reflect the manufacturer’s batch testing for this compound.
Research Areas
GH Axis Stimulation & Pulsatility Research CJC-1295 Without DAC is the standard GHRH-receptor tool compound in pulsatile GH secretagogue studies. Unlike CJC-1295 With DAC, which produces sustained supraphysiological GH elevation over days, the Without DAC variant generates a discrete GH pulse with ~30-min window of activity — more closely approximating endogenous GHRH burst release from the hypothalamus. This kinetic profile is preferable when investigating somatotroph desensitisation, GH feedback loops, or physiological pulse modelling. Synergistic GH Release (GHRH + GHRP Combination Studies) Combining a GHRHR agonist (CJC-1295 Without DAC) with a GHSR-1a agonist (ipamorelin, GHRP-2, or GHRP-6) produces synergistic GH release exceeding the sum of each compound alone. This synergy occurs because GHRHR activation increases cAMP-dependent somatotroph excitability, while GHSR-1a activation triggers intracellular calcium release — two independent upstream pathways converging on GH exocytosis. The ipamorelin + CJC-1295 Without DAC combination is the most studied pairing due to ipamorelin’s selectivity profile. Growth & Body Composition Modelling In hypophysectomised and GH-deficient rodent models, CJC-1295 Without DAC restores GH pulsatility and partially reverses GH-deficiency phenotypes including lean mass loss, fat accumulation, and reduced IGF-1 levels. Bone mineral density studies in aged rodent models document modest anabolic effects on trabecular bone with pulsatile GHRH stimulation protocols. These models are used to characterise the downstream somatic effects of GH axis activation without exogenous GH administration. Comparison with Sermorelin Sermorelin (GHRH 1–29 native sequence) and CJC-1295 Without DAC are structurally related. The four amino acid modifications in CJC-1295 Without DAC increase metabolic stability while retaining full GHRHR agonism. Comparative studies in rat models show CJC-1295 Without DAC produces a larger and more sustained GH peak than equimolar sermorelin due to resistance to DPP-IV cleavage. This makes CJC-1295 Without DAC the preferred research tool when half-life extension is desirable without the sustained release characteristics of the DAC version. ## Sourcing CJC-1295 Without DAC From China
CJC-1295 Without DAC is available through our platform as a china peptide sourced directly from an established Chinese manufacturer. Three points define how we handle it:
- Factory-direct, not trader-sourced. We confirm availability and specification with the manufacturer before the order is confirmed. There is no intermediary resale of unknown-origin vials in this catalog.
- Specification before shipment. The purity and concentration specification shown on this page is the manufacturer’s batch specification. Product-specific quality-control information travels with the order.
- Research-use discipline. Like every listing in our catalog, CJC-1295 Without DAC is supplied for laboratory research use only, under strict research-use terms.
For buyers comparing chinese peptides suppliers, the practical test is whether the seller can name the manufacturer and show the batch documentation. We work the other way around: the manufacturer and the documentation are the offer. Browse the full catalog or see how sourcing works.
Compound Profile
CJC-1295 Without DAC — also referred to as Modified GRF (1-29) or Mod GRF 1-29 — is a synthetic 29-amino acid analogue of endogenous growth hormone-releasing hormone (GHRH). It is derived from the biologically active N-terminal fragment of native GHRH (residues 1–29) with four amino acid substitutions: Ala⁸→Gln, Ala¹⁵→Ala (D-Ala), Ala¹⁸→Gln, and Phe²⁹→Tyr. These modifications extend plasma half-life from the ~7 minutes of native GHRH(1-29) to approximately 30 minutes by blocking DPP-IV cleavage at position 2 and reducing peptidase susceptibility at other sites. Critically, it lacks the Drug Affinity Complex (DAC) lysine modification present in CJC-1295 With DAC, so it does not bind albumin and retains a pulsatile pharmacokinetic profile rather than producing sustained GH elevation. The compound is widely used in GH secretagogue research as the GHRH component of pulse-mimicking study designs. Its pulsatile kinetics align with the endogenous pattern of hypothalamic GHRH release, making it useful for models where maintaining physiological GH pulsatility is important. In most published preclinical protocols, CJC-1295 Without DAC is co-administered with a GHSR-1a agonist — most commonly ipamorelin — to achieve synergistic GH pulse amplification through independent receptor pathways (GHRHR and GHSR-1a respectively). Peptides of China supplies CJC-1295 Without DAC as lyophilized powder, ≥98% purity by HPLC, confirmed by mass spectrometry. Every batch is purity-tested by the manufacturer. Suitable for reconstitution in aqueous research buffers. All product is for laboratory research use only.
Profile
Available Variants
| Name | Strength | Pack Size | Purity | Availability |
|---|---|---|---|---|
| CJC-1295 Without DAC | 2 mg | 10 vials | ≥98% | In Stock |
| CJC-1295 Without DAC | 5 mg | 10 vials | ≥98% | In Stock |
| CJC-1295 Without DAC | 10 mg | 10 vials | — | In Stock |
| CJC-1295 Without DAC | 10 mg | 10 vials | ≥98% | In Stock |
Specification Highlights
Quality & Testing
Testing method: HPLC / LC-MS . Products are supplied against the specification shown on the applicable product page. The standard catalog purity specification is ≥98% unless otherwise stated. Product-specific specifications and quality-control information may vary by compound and batch. Available documentation: .
**Where provided, these documents reflect the manufacturer’s batch testing for this compound.
Research Areas
GH Axis Stimulation & Pulsatility Research CJC-1295 Without DAC is the standard GHRH-receptor tool compound in pulsatile GH secretagogue studies. Unlike CJC-1295 With DAC, which produces sustained supraphysiological GH elevation over days, the Without DAC variant generates a discrete GH pulse with ~30-min window of activity — more closely approximating endogenous GHRH burst release from the hypothalamus. This kinetic profile is preferable when investigating somatotroph desensitisation, GH feedback loops, or physiological pulse modelling. Synergistic GH Release (GHRH + GHRP Combination Studies) Combining a GHRHR agonist (CJC-1295 Without DAC) with a GHSR-1a agonist (ipamorelin, GHRP-2, or GHRP-6) produces synergistic GH release exceeding the sum of each compound alone. This synergy occurs because GHRHR activation increases cAMP-dependent somatotroph excitability, while GHSR-1a activation triggers intracellular calcium release — two independent upstream pathways converging on GH exocytosis. The ipamorelin + CJC-1295 Without DAC combination is the most studied pairing due to ipamorelin’s selectivity profile. Growth & Body Composition Modelling In hypophysectomised and GH-deficient rodent models, CJC-1295 Without DAC restores GH pulsatility and partially reverses GH-deficiency phenotypes including lean mass loss, fat accumulation, and reduced IGF-1 levels. Bone mineral density studies in aged rodent models document modest anabolic effects on trabecular bone with pulsatile GHRH stimulation protocols. These models are used to characterise the downstream somatic effects of GH axis activation without exogenous GH administration. Comparison with Sermorelin Sermorelin (GHRH 1–29 native sequence) and CJC-1295 Without DAC are structurally related. The four amino acid modifications in CJC-1295 Without DAC increase metabolic stability while retaining full GHRHR agonism. Comparative studies in rat models show CJC-1295 Without DAC produces a larger and more sustained GH peak than equimolar sermorelin due to resistance to DPP-IV cleavage. This makes CJC-1295 Without DAC the preferred research tool when half-life extension is desirable without the sustained release characteristics of the DAC version.